Metastatic mesenchymal chondrosarcoma showing a sustained response to cabozantinib: A case report

Mesenchymal chondrosarcoma is a rare and aggressive sarcoma subtype with high risk for distant metastases and poor prognosis. Currently NCCN- and ESMO-Guidelines recommend using Ewing sarcoma protocols as standard treatment. Nevertheless, in localized disease overall 5-year survival rates are below...

Descripción completa

Detalles Bibliográficos
Autores principales: Blum, Veronika, Andrei, Vanghelita, Ameline, Baptiste, Hofer, Silvia, Fuchs, Bruno, Strobel, Klaus, Allemann, Anna, Bode, Beata, Baumhoer, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791217/
https://www.ncbi.nlm.nih.gov/pubmed/36578930
http://dx.doi.org/10.3389/fonc.2022.1086677

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791217/
https://www.ncbi.nlm.nih.gov/pubmed/36578930
http://dx.doi.org/10.3389/fonc.2022.1086677

Ejemplares similares